Evidence map›Paper›PMID 42232598›Full record

ArticleOncology research2026

Identification of

Dat Quoc Tran, Mayu Takeda, Eiji Sugihara, Tetsuya Tsukamoto, Yasushi Hoshikawa, Yasuyoshi Mizutani, Kazuya Shiogama, Naoya Asai, Atsuko Niimi, Makoto Sumitomo and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Dat Quoc TranDepartment of Molecular Oncology, Fujita Health University, Toyoake, Japan.ORCID https://orcid.org/0009-0004-5081-144X
Mayu TakedaOncology Innovation Center, Fujita Health University, Toyoake, Japan.ORCID https://orcid.org/0000-0003-4182-1967
Eiji SugiharaOncology Innovation Center, Fujita Health University, Toyoake, Japan.ORCID https://orcid.org/0000-0002-3233-1045
Tetsuya TsukamotoOncology Innovation Center, Fujita Health University, Toyoake, Japan.ORCID https://orcid.org/0000-0002-7502-8724
Yasushi HoshikawaDepartment of Thoracic Surgery, Fujita Health University, Toyoake, Japan.
Yasuyoshi MizutaniDepartment of Molecular Oncology, Fujita Health University, Toyoake, Japan.
Kazuya ShiogamaDepartment of Pathology and Cytopathology, Fujita Health University, Toyoake, Japan.ORCID https://orcid.org/0000-0002-5228-1575
Naoya AsaiDepartment of Pathology, Fujita Health University, Toyoake, Japan.
Atsuko NiimiDepartment of Molecular Oncology, Fujita Health University, Toyoake, Japan.ORCID https://orcid.org/0009-0004-0869-3144
Makoto SumitomoOncology Innovation Center, Fujita Health University, Toyoake, Japan.
Hideyuki SayaOncology Innovation Center, Fujita Health University, Toyoake, Japan.ORCID https://orcid.org/0000-0001-6610-1902
Motoshi SuzukiDepartment of Molecular Oncology, Fujita Health University, Toyoake, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Adenocarcinoma of LungBRCA2 ProteinGerm-Line MutationLung NeoplasmsNeoplasms, Multiple PrimaryAdultAgedFemaleGenetic Predisposition to DiseaseHumansMaleMiddle AgedProto-Oncogene MasBRCA2 ProteinBRCA2 protein, humanMAS1 protein, humanProto-Oncogene MasadenocarcinomaBRCA2 DNA repair associatedgermline pathogenic variantsintrapulmonary metastasisMultiple primary lung cancer

Identifiers

PMID42232598
PMCPMC13223183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.